Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GenPlus
New Taipei City, Taiwangenplus.com.tw ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
GenPlus is a specialty pharmaceutical company headquartered in Taiwan, dedicated to the development of innovative drug delivery systems. The company specializes in the 505(b)(2) regulatory pathway, focusing on transdermal patches and oral thin films to enhance the delivery of established molecules. Their primary therapeutic focus is on central nervous system (CNS) disorders, including Alzheimer's and Parkinson's diseases, as well as pain management. GenPlus maintains integrated capabilities for formulation research, clinical development, and GMP-compliant manufacturing. By improving patient compliance and reducing side effects, the company aims to provide significant clinical value in the global healthcare market.
- Therapeutic areas
- UrologyNeurology
- Modalities
- Small moleculeTransdermal patchOral thin film
- Industry
- Biotech
Beyond the preview
Go deeper on GenPlus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenPlus.